First Biosimilar Launched In The U.S. After Court Denies Amgen's Injunction

The first FDA-approved biosimilar, Sandoz's Zarxio, was launched in the United States Thursday (Sept. 3) after a federal appeals court denied Amgen's emergency motion to block Sandoz from marketing its product. "As the pioneer and global leader in biosimilars, Sandoz has maintained a commitment to bringing high-quality biosimilar medicines to patients and healthcare professionals around the world," said Richard Francis, Global Head of Sandoz. "With the launch of Zarxio, we look forward to increasing patient, prescriber and payor access to...